Skip to main content

Table 1 Univariate analysis of clinical parameters

From: An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era

  Number (%) Univariate analysis
3Y–PFS (%) P value 3Y–OS (%) P value
Gender
 Male 312(55.3%) 74.4% 0.101 80.4% 0.017
 Female 252(44.7%) 78.0%   92.0%  
Age, years
  ≤ 60 381(67.6%) 78.6% 0.062 88.3% 0.002
  > 60 183(32.4%) 70.2%   72.1%  
Ann Arbor stage
 I,II 310(55.0%) 85.6% <0.001 91.8% <0.001
 III,IV 254(45.0%) 64.4%   72.8%  
LDH(U/L)
  ≤ 245 337(59.8%) 84.8% <0.001 91.6% <0.001
  > 245 227(40.2%) 62.8%   70.6%  
ECOG PS
 0,1 466(82.6%) 79.9% <0.001 86.3% <0.001
  ≥ 2 98(17.4%) 57.2%   68.5%  
Extranodal sites
  ≤ 1 416(73.8%) 80.3% <0.001 88.2% 0.017
  > 1 148(26.3%) 62.5%   67.2%  
IPI
 L 309(54.8%) 94.1% <0.001 87.6% <0.001
 LI 96(17.0%) 84.5%   72.5%  
 HI 96(17.0%) 64.3%   57.0%  
 H 63(11.2%) 55.4%   51.5%  
CRP (mg/L)
  ≤ 8.6 357(63.3%) 83.7% <0.001 91.2% <0.001
  > 8.6 207(36.7%) 64.0%   70.9%  
Albumin levels (g/L)
  < 41.5 266(47.2%) 67.0% <0.001 72.8% <0.001
  ≥ 41.5 298(52.8%) 83.9%   92.3%  
LMR
  ≤ 2.7 348(61.7%) 63.2% <0.001 70.0% <0.001
  > 2.7 216(38.3%) 83.9%   91.4%  
NLR
  ≤ 4.6 436(77.3%) 82. 3% <0.001 89.0% <0.001
  > 4.6 128(22.7%) 60.9%   68.8%  
PLR
  ≤ 187.4 389(69.0%) 81.2% <0.001 87.9% <0.001
  > 187.4 175(31.0%) 69.1%   76.6%  
Fibrinogen levels (g/L)
  ≤ 3.8 359(63.6%) 82.9% 0.001 88.3% 0.001
  > 3.8 205(36.4%) 68.8%   76.2%  
  1. Abbreviations: 3Y–PFS 3-year progression-free survival, 3Y–OS 3-year overall survival, LDH Lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, IPI International Prognostic Index, L Low, LI Low-intermediate, HI High-intermediate, H High, CRP C-reactive protein, LMR Lymphocyte-to-monocyte Ratio, NLR Neutrophil-to- lymphocyte ratio, PLR Platelet-to- lymphocyte ratio